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Genetically Modified Organisms: A New 
Proposal Regarding Deliberate Release 
INTRODUCTION 
Biotechnology refers to the development of techniques using 
organisms, or parts of organisms, to provide or improve goods 
or services. l Within the field of biotechnology, advancements in 
genetic engineering have yielded microorganisms known as ge-
netically modified organisms (CMOs)-organisms or microorga-
nisms in which genetic material has been altered in a manner 
that does not occur naturally by mating or recombination. 2 De-
liberate release is the intentional introduction of CMOs into the 
environment without provision for containment.3 CMOs may be 
released into the atmosphere for various environmental and ag-
ricultural purposes, such as to degrade toxic waste, or to propa-
gate new varieties of cultivated plants. 4 The release of CMOs, 
however, entails environmental risks such as the possibility of 
accidental release or unforeseen negative effects on the ecosys-
tem.5 Thus, as biotechnology becomes more prevalent, a greater 
need emerges for coherent and effective safeguards to protect 
people and the environment. 6 
The European Community'S (EC or Community) environmen-
tal legislation in the 1990s has led to an increase in precautionary 
I WORLD HEALTH ORGANIZATION (WHO), Health Impact of Biotechnology, Report on a WHO 
Working Group, SWISS BIOTECH, No.5, 1984. 
2 Dr. Claus-Joerg Ruetsch & Terry R. Broderick, New Biotechnology Legislation in the 
European Community and Federal Republic of Germany, 18 INT'L Bus. LAW. 408, 408 (1990). 
3Id. 
4 WHO, supra note 1. 
5 Biotechnology: Parliament Calls for More Stringent Controls on Genetically Modified Organ-
isms, Eur. Rep. (Eur. Info. Serv.), Mar. 17, 1990, available in LEX IS, Europe Library, 
ECInfo File [hereinafter Stringent Controls]. 
For example, if a new type of pesticide-resistant wheat is devised, the pesticide-resistant 
genes may be passed accidentally to a weed. Thus, the risk of disrupting ecological cycles 
is considerable. 
6 See, e.g., Council Decision 92/218 of 26 March 1992 Adopting a Specific Research and 
Technological Development Programme in the Field of Biotechnology (1990 to 1994), 
19920.]. (L 107) 1. 
The royal commission on environmental pollution reported 28 genetically modified 
organism (GMO) releases in Great Britain alone as of mid-1991. See Michael McCarthy, 
Keeping a Step Ahead of Genetic Mistakes, THE TIMES (London), June 19, 1991, available in 
LEX IS, Europe Library, EClnfo File. 
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and preventive policies. 7 Biotechnology is a prime example of the 
European regulatory philosophy.s Although the United States has 
no regulations regarding genetic engineering, the Community, 
as well as each European nation, regulates biotechnology to a 
certain degree.9 On November 4, 1991, the Council of the Eu-
ropean Communities (Council) addressed a Decision to the Mem-
ber States regarding the deliberate release of CMOs.IO Council 
Decision 911596 specifies the content and format of the notifica-
tion every researcher or manufacturer must submit to a national 
authority prior to the intentional release of any CMO.ll 
This Comment will assess the potential effectiveness of Council 
Decision 911596 in light of the EC's environmental policies. Part 
I briefly discusses EC environmental policy prior to and after the 
Single European Act of 1987 (SEA). Part II describes the Euro-
pean biotechnology industry and the 1990 Directives regarding 
CMOs. Part III examines Decision 911596 by focusing on its 
provisions, anticipated effects, and likelihood of enforcement. 
This Comment concludes that Summary Notification has the po-
tential to be an effective and efficient means of regulating ad-
vancements in biotechnology in the interest of environmental 
protection. 
1. EUROPEAN COMMUNITY ENVIRONMENTAL POLICY 
Environmental policies raise complex problems which require 
balancing the competing interests of industry and the concerns 
of those who advocate safeguarding natural resources and human 
health. 12 Environmental safeguards are a particular point of con-
tention in the EC; environmental provisions must be introduced 
gradually, economic and regional specialties must be taken into 
71992 Euroscope: Environment, Coopers & Lybrand, Apr. 2, 1992, available in LEXIS, 
Europe Library, Alleur File, at *1 [hereinafter Coopers & Lybrand, Environment). 
8 See, e.g., 1992 Euroscope; Pharmaceuticals, Coopers & Lybrand, Aug. 20, 1992, available 
in LEXIS, Europe Library, AHeur File, at *17.6, *17.7 [hereinafter Coopers & Lybrand, 
Pharmaceuticals). 
9 Catherine Arnst, EC Report to Propose Biotechnology Incentives, Reuters, Apr. 15, 1991, 
available in LEXIS, Nexis Library, Omni File; Ruedi Sand meier, Political Roadblocks Hinder 
Biotechnology Industry, S. F. CHRON., June 3, 1991, at B2. 
10 Council Decision 91/596 of 4 November 1991 Concerning the Summary Notification 
Information Format Referred to in Article 9 of Directive 90/220 on the Deliberate Release 
Into the Environment of Genetically Modified Organisms, 1991 OJ. (L 322) 1. 
II See id. 
12 See generally ZYGMUNT J.B. PLATER, ENVIRONMENTAL LAW POLICY; A COURSEBOOK ON 
LAW, NATURE & SOCIETY (1992). 
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account, and the possibility of transferring costs to consumers 
must be considered. 13 Environmental legislation, including any 
measure regulating biotechnology, is assessed according to 
whether protection of the environment can be attained better by 
measures at the Community level or at the level of the Member 
States. 14 It is important to realize that EC environmental policy 
neither supplants national environmental policy nor renders it 
redundant. 15 
A. Environmental Policy Before the Single European Act 
Protection of the environment was not among the Community's 
objectives in 1958; 16 the Treaty of Rome (Treaty) did not even 
include the concepts "environment" or "environmental policy."17 
During the last three decades, however, the Community has de-
veloped an integrated approach to implement stricter standards 
for environmental protection. IS In the absence of specific legal 
authorization, the Community has invoked Articles 2, 100, and 
235 of the Treaty to achieve its environmental objectives. 19 The 
Community has also enacted environmental measures by using 
binding legal acts pursuant to Articles of the Treaty.2o 
While Articles 2, 100, and 235 have been used to attain envi-
ronmental objectives, Article 30 is an important restriction on 
I3 Ludwig Kramer, The Single European Act and Environment Protection: Reflections on 
Several New Provisions in Community Law, 24 COMMON MKT. L. REV. 659, 669 (1987). 
14 Single European Act, Feb. 17, 1986, art. 130r(4), 1987 OJ. (L 169) 1 [hereinafter 
SEA]. 
15 Kramer, supra note 13, at 669. 
16 Coopers & Lybrand, Environment, supra note 7, at *2.1; see generally TREATY ESTAB-
LISHING THE EUROPEAN ECONOMIC COMMUNITY [EEC TREATY]. 
17 Fourth Environment Action Programme, 1987 OJ. (C 328) 6. 
18 Kramer, supra note 13, at 663. Article 2 of the EEC Treaty states the Community's 
objectives broadly: "[to] establish a common market and progressively approximat[e] the 
economic policies of Member States, to promote throughout the Community a harmonious 
development of economic activities, a continuous and balanced expansion, an increase in 
stability, an accelerated raising of the standard of living and closer relations between the 
Member States belonging to it." 
Article 100 of the Treaty of Rome addresses the need for harmonization of national 
provisions which have a direct effect on the establishment or functioning of the Common 
Market. 
Article 235 authorizes action by the Community which appears necessary to attain any 
one of the Community's stated objectives in the course of the operation of the Common 
Market. 
19 Coopers & Lybrand, Environment, supra note 7, at *2.1. 
20 Kramer, supra note 13, at 688. 
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any environmental measure undertaken by the EC.21 As inter-
preted by the European Court of Justice (ECJ), Article 30 pro-
hibits all measures enacted by Member States which are capable 
of hindering intra-Community trade, either directly or indirectly, 
actually or potentially.22 Nonetheless, since 1973 the EC has 
adopted four successive Environment Action Programmes.23 
The first two Environment Action Programmes identified nec-
essary Community-wide remedial actions,24 and resulted in re-
active rather than proactive policy.25 The Third Environment 
Action Programme focused on preventive measures by integrat-
ing environmental requirements with the planning and execution 
of further economic and social development.26 The Community's 
earliest regulations regarding biotechnology were also promul-
gated at this time; they applied to areas such as foodstuffs, phar-
maceuticals, and agriculture. 27 In 1985, the Commission autho-
rized a Biotechnology Research Action Programme to develop 
risk assessment techniques specific to the biotechnology indus-
try.28 The Commission expressed its belief that potential risks 
should be evaluated as far in advance of production as possible 
to allow for preventive action.29 
B. Environmental Policy After the Single European Act 
The current Environment Action Programme is premised on 
the belief that high standards of environmental protection are an 
21 Id.; EEC TREATY arts. 2, 30, 100,235. 
22 Kramer, supra note 13, at 688. 
23 Each Environment Action Programme spanned four or five years. The first three 
commenced in 1973, 1977, and 1983. The Fourth Environment Action Programme is for 
the six-year period 1987-1992. Fourth Environment Action Programme, supra note 17. 
24 1973 ].0. (C 112) 20; Coopers & Lybrand, Environment, supra note 7, at 2.1. 
25 Issues were addressed as they occurred, rather than before they became a problem. 
See Coopers & Lybrand, Environment, supra note 7, at 2.1. The Community's environmental 
policy at this time concentrated on trade creation, industrial pollution, and issues brought 
to the forefront by strong public pressure. Id. 
26 An example of such preventive measures is Directive 85/337, promulgated during 
the Third Environment Action Programme. It requires an assessment of the effects of 
certain public and private projects on the environment before the project begins. 1985 
OJ. (L 175) 7. 
27 Fourth Environment Action Programme, supra note 17, at 4.4.1. In addition, the EC 
instituted policies in advance of other nations to manage the development of recombinant 
DNA research. Id. 
28Id. at 4.4.3. In conjunction with the philosophy of the Third Action Programme, the 
Biotechnology Research Action Programme was created out of concern that with a rapid 
development in the biotechnology industry, detrimental effects on the environment might 
multiply rapidly if appropriate precautions were not taken. [d. 
29 [d. at 4.4.4. 
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economic imperative, and that Community industry will not be 
successful unless it can satisfy public demands for environmen-
tally safe goods. 3D The Action Programme's agenda reflects that 
of the SEA, which amended the Treaty of Rome by updating and 
refining many of its provisions.3! The SEA incorporated the Com-
munity's environmental objectives by adding a new chapter on 
the environment: Articles 130r, 130s, and 130t.32 In addition, 
Title VII of the SEA specifically empowers the Community to 
protect the environment.33 
The first two objectives outlined in Article 130r(l) of the SEA 
encompass biotechnology measures committed to preserving and 
protecting the environment and to improving conditions of hu-
man health.34 The Council has also outlined a more specific de-
velopment program for the field of biotechnology.35 The EC's 
goal of internal harmonization prompted concerns that enforce-
ment of stringent environmental standards would result in the 
overregulation of the biotechnology industry.36 The Commission 
therefore strongly advocated a single procedure, now referred to 
as Summary Notification, for assessment and notification on the 
basis of three criteria: quality, safety, and effectiveness. 37 
II. THE BIOTECHNOLOGY INDUSTRY AND THE 1990 DIRECTIVES 
The focus of the Community's environmental policy has shifted 
from "continuous and balanced expansion" under the Treaty of 
Rome to the promotion of "sustainable and non-inflationary 
growth respecting the environment" under the SEA.38 Prior to 
Directives 90/219 and 90/220, which established a European no-
tification and permit system for GMO releases,39 biotechnology 
30Id. at 1.3. 
31 Coopers & Lybrand, Environment, supra note 7, at *2.2. 
32 SEA, supra note 14. Article 130r(l) describes the Community objectives as: (1) to 
preserve, protect, and improve the quality of the environment; (2) to contribute toward 
protecting human health; and (3) to ensure a prudent and rational utilization of natural 
resources. 
33 Coopers & Lybrand, Environment, supra note 7, at *2.1. 
34 SEA, supra note 14; Kramer, supra note 13, at 664. 
35 See Council Decision 92/218, supra note 6. 
36 See Biotechnology: Proposals for New EEC Strategy Receive Green Light, Eur. Rep. (Eur. 
Info. Serv.), Apr. 20, 1991, available in LEXIS, Europe Library, ECInfo File [hereinafter 
Biotechnology]. 
37Id. 
38 Coopers & Lybrand, Environment, supra note 7, at *2.1. 
39 Council Directive 90/219, 1990 OJ. (L 117) 1; Council Directive 90/220, art. 9, 1990 
OJ. (L 117) 15. 
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regulation existed in varying degrees in the Member States. Laws 
in Germany, Denmark, and the Netherlands virtually banned the 
release of GMOs, while other countries had no legislation on the 
issue.4o This lack of uniformity among national provisions has 
resulted in a fragmented biotechnology database which places the 
EC's approximately 800 firms at a disadvantage relative to the 
United States and Japan.41 Patchwork regulation may also ex-
plain, in part, why investment in European biotechnology is cur-
rently a fraction of what it is in the United States.42 
Directives 90/219 and 90/220 introduced a common legislative 
framework and eliminated existing disparities between Member 
States' regulations for the evaluation and reduction of potential 
risks involved in the use of GMOs.43 The Commission enumer-
ated nine areas of concern regarding the contained use or delib-
erate release of GMOs,44 and required Member States to ensure 
that all appropriate measures are taken to avoid adverse effects 
on human health or the environment.45 Although both Directives 
excluded products already regulated by the Community,46 rep-
resentatives of the biotechnology industry immediately accused 
the EC of hampering industry development with such stringent 
regulations. 47 
The first Directive, 90/219, addresses contained or laboratory 
use of GMOs.48 It is intended to establish a permanent inventory 
within each Member State to monitor developments and trace 
40 Arnst, supra note 9. 
41 Biotechnology, supra note 36. Of the worldwide biotechnology patents obtained by the 
end of 1989, the United States accounted for 41 percent, Japan 36 percent, and Europe 
19 percent. None of the world's five top-selling bioengineered drugs were made in 
Europe. Arnst, supra note 9. 
42 See Arnst, supra note 9. 
43 See Ruetsch & Broderick, supra note 2, at 408. 
44 The Commission focused on: (1) the nature of the organisms produced; (2) the 
production processes used; (3) operating discharges to the environment; (4) waste disposal 
and management practices; (5) accident prevention; (6) application methods and intended 
sites for release; (7) detection, monitoring, and control of survival, multiplication, and 
dissemination; (8) exposed populations; and (9) effects of the organisms on humans and 
other species. Fourth Environment Action Programme, supra note 17, at 4.4.6. 
45 Ruetsch & Broderick, supra note 2, at 408. 
46 These products are human and veterinary pharmaceuticals, foodstuffs, additives, 
feedingstuffs, plants, and animals. Directives Could Cripple Biotech Sector, Critics Warn, Ex-
ternal Impact of European Unification, Apr. 6, 1990, available in LEXIS, Europe Library, 
ECInfo File [hereinafter Directives Could Cripple]. 
47 Arnst, supra note 9. 
48 See Council Directive 90/219, supra note 39. 
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the origin of negative effects resulting from the use of CMOS.49 
Directive 90/220, the second directive, instituted controls on the 
deliberate release of CMOs into the environment.5o Articles 5 
through 9 of this Directive provide for release of CMOs into the 
environment for research, development, or purposes other than 
placing products on the market.51 According to this directive, 
information must be made available to the local population prior 
to a planned CMO release in the area. 52 In addition, the use of 
a CMO may not proceed without the consent of a competent 
authority. 53 
Both Directives unequivocally place the burden on the inno-
vator to identify and thoroughly assess all relevant risks in ad-
vance.54 The Council's goal is to supplement evaluations through 
close monitoring of CMOs after their release.55 The user of the 
CMO must submit adequate information to the competent au-
thorities in the Member State where the release will take place.56 
Article 9 is pivotal in this regard, in that it creates a procedure 
for sharing specific information among Member States about the 
characteristics of CMOs and the intended release.57 Article 9 thus 
provides authorization for Decision 911596-the establishment of 
summary notification for the deliberate release of CMOs.58 
III. COUNCIL DECISION 911596 
A. A New Regulatory Decision 
Council Decision 911596 is part of an integrated strategy to 
harmonize national legislation and to promote the safe develop-
ment of biotechnology. 59 The Decision creates a regulatory system 
49 See Uf. A controversial provision requires industrialists and research workers to assume 
the responsibility for any harm caused and to take out insurance policies to that effect. 
50 See Council Directive 90/220, supra note 39. 
51 [d. at arts. 5-9; see also Ruetsch & Broderick, supra note 2, at 409. 
52 Council Directive 90/220, supra note 39, at art. 9. 
53 Fourth Environment Action Programme, supra note 17, at 4.4.4. Each Member State 
designates the competent authority to receive the information. Council Directive 90/220, 
supra note 39, at arts. 4(2), 4(3). 
54 See Council Directive 90/220, supra note 39, at arts. 1(1),4(1). 
55 Proposal for a Council Directive on the Deliberate Release to the Environment of 
Genetically Modified Organisms, COM(90)160 at 57 [hereinafter Proposal for a Council 
Directive]. 
56 [d. at art. 5(1). 
57 See Council Directive 90/220, supra note 39, at art. 9. 
58 See Uf. at art. 9. 
59 See Ruetsch & Broderick, supra note 2, at 408. 
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designed to improve European industry's ability to compete with 
the United States and Japan.60 It requires researchers, or the 
competent authority overseeing the project, to provide detailed 
information about the introduction of the GMO.61 Toward that 
end, researchers must answer 56 multiple-part questions grouped 
in eight categories, which are notable for their breadth and com-
prehensive coverage.62 
The first Summary Notification category requires researchers 
to characterize the GMO by identifying and describing the pur-
pose of the microorganism.63 The second and third categories 
request detailed information relating to the recipient or parental 
organism as well as information about the genetic modification.64 
The fourth category focuses on the release of the GMO-the 
purpose, location, method and amount of the intended release, 
and procedures to avoid or minimize the spread of the GMO 
beyond the release site.65 
The fifth part of the Summary Notification attempts to gauge 
the potential impact on the environment. Under this provision, 
the researcher must evaluate the target organism, the potential 
affects on other organisms, and the ecosystem in which the GMO 
will be introduced.66 The sixth and seventh categories request 
information relating to monitoring, post-release, and waste treat-
ment.67 The final set of questions, and perhaps the most impor-
tant, require the preparation of emergency response plans.68 
It is interesting to note that the Annex to the Decision explicitly 
states that Summary Notification is not designed to contain all 
the information required for carrying out a detailed environ-
mental risk assessment.69 Summary Notification is similar to the 
EC assessment process in that it is intended to predict the direct 
and indirect effects of a project on human beings, flora, fauna, 
6°Id. 
61 See generally Council Decision 911596, supra note 10, at ANNEX. The bulk of Decision 
911596 is the actual format of the required Summary Notification researchers will utilize. 
See id. 
62 See Council Decision 911596, supra note 10. 
63Id. at 4-7. 
64 Id. at 7-10. 
65Id. at 11-12. 
66Id. at 12-13. 
67Id. at 13-15. 
68Id. at 16. 
69Id. at ANNEX. 
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soil, water, air, climate, and landscape. 7o The procedures differ, 
however, in that Summary Notification does not require a consid-
eration of the effect of CMOs on material assets and cultural 
heritages.71 
More significantly, detailed environmental risk assessments re-
quire consultation with the competent authorities, all affected 
Member States, and the public. 72 The project may not proceed 
until all opinions are evaluated and the public is informed of the 
decision.73 Summary Notification does not contain these stric-
tures. In q.ddition, Summary Notification imposes a minimal bur-
den on researchers and manufacturers.74 The Council's Proposal 
for Directive 90/220 provides that the notification should consist 
of information already available to businesses.75 Moreover, the 
Proposal states that "notifications will not be required of the final 
users of the product, i.e. farmers, environmental clean-up com-
panies, etc."76 It would seem, therefore, that compliance with 
Summary Notification is comparatively limited in scope and IS 
less burdensome than a complete environmental assessment. 
B. The Anticipated Effects of Decision 91/596 
Most industry experts and participants agree that some controls 
are necessary, and even beneficial, in assessing the effects of 
releasing CMOs.77 Decision 911596 is the equivalent of codifying 
risk evaluation, which is normally undertaken by researchers and 
manufacturers.78 The Summary Notification format, at best, fa-
cilitates what might otherwise be a complex and time-consuming 
process. Yet industry reaction to Decision 911596 is divided; some 
company officials are relieved to have new rules to eliminate the 
growing confusion of national standards, whereas others fear 
such regulatory controls in biotechnology will undermine the 
70 Directive 85/337, supra note 26. 
71 Compare Council Decision 911596, supra note 10, at ANNEX, with Directive 85/337, 
supra note 26. 
72 Directive 85/337, supra note 26. 
73 [d. 
74 See Proposal for a Council Directive, supra note 55, at 57. 
75 [d. 
76 [d. 
77 See, e.g., Directives Could Cripple, supra note 46. 
78 See Coopers & Lybrand, Pharmaceuticals, supra note 8, at *17.7. 
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ability of biotechnology products to compete with similar prod-
uctS.79 
A major concern of industry participants is the full-disclosure 
requirement of Decision 911596, because the researchers must 
reveal details of the development of the microorganism and its 
intended use.80 The Commission has made it clear, however, that 
confidential information supplied to authorities will be kept secret 
to protect the competitive position of the notifier.81 Nonetheless, 
depending on how confidential information is defined, an im-
portant question is whether the public will have the right to obtain 
detailed biotechnology information under a new Directive on 
public access to environmental information.82 
The most important question, of course, is whether Decision 
911596 will effectively accomplish its intended purpose. There 
are at least two incentives for Member States to enact measures 
to enforce the Decision. The first is that the Community's envi-
ronmental laws can be enforced by local and national courts, as 
well as by the ECJ.83 Accordingly, the ECl has the authority to 
sanction Member States for failure to comply. 84 
The second reason Member States will want to comply with 
Decision 911596 is the ability of private citizens to complain di-
rectly to the Commission about violations of environmental law. 85 
This is an important motivation given the belief, widely held by 
biotechnology industry officials, that the most critical issue facing 
biotechnology in Europe is public perceptions.86 Thus, in view of 
79 [d. 
80 See Council Decision 911596, supra note 10, at 7-12. 
81 See Council Decision 92/146, 19920.]. (L 60) 1. 
82 Directive 90/313 is modelled on the U.S. Freedom of Information Act and establishes 
a common standard for public access to government files for all citizens in the Community. 
Individuals will have a right to obtain environmental information on the state of air, 
water, soil, flora, fauna, and natural areas. The Directive will come into effect January 1, 
1993. 19900.]. (L 158) 35. Its terms do not exclude biotechnology or genetically engi-
neered products. Coopers & Lybrand, Environment, supra note 7, at *3.2. 
8' [d. at 2.1. 
84 EEC TREATY art. 171. The EC] recently held that the failure to adopt measures 
needed to implement a Community directive constituted an infringement of article 171 
of the EEC Treaty for which the Member States could be ordered to pay damages. Joined 
Cases 227-230/85, Commission of the European Communities v. Kingdom of Belgium, 
1 CEC(CCH) 626, 632-33 (1990). The court imposed costs under article 69(2) of the 
Rules of Procedure. 
85 See id. 
86 Arnst, supra note 9. One may only speculate why industry officials are convinced that 
the public plays a more important role in Europe than in the United States or Japan. It 
may be that the public in Europe is generally more aware of, and concerned with, 
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the serious potential threat to the environment, the very real 
threat of sanctions by the ECl for non-compliance, and the veiled 
threat of consumer dissatisfaction, the Summary Notification es-
tablished by Decision 911596 will likely be implemented and en-
forced by the Member States.87 
CONCLUSION 
Decision 911596 demonstrates that the EC is again leading other 
countries in managing environmental risks. Although the United 
States and 1 apan have chosen to ignore the necessity of regulating 
the rapidly developing biotechnology sector, the EC has enacted 
comprehensive preventive legislation. The potential drawbacks 
of the Decision reflect the need to enact threshold standards 
which will be enforceable and effective. Any shortcomings of 
Summary Notification will be addressed when Community-wide 
standards are adapted to the needs of individual Member States. 
This flexibility is consistent with the EC's environmental objectives 
and its goal of internal harmonization. Overall, Summary Noti-
fication for the deliberate release of CMOs is a unique and po-
tentially expeditious way of handling the complex issues raised 
by sophisticated technologies. 
Denise Chicoine 
environmental issues due to Europe's traditional overcrowding and limited resources-
problems which have finally come to the forefront in other countries in the last decade. 
87 The 1990 biotechnology directives, Directive 90/219 and 90/220, required implemen-
tation by the Member States by October 23, 1991. UK: Department of the Environment-
Regulations on Genetically Modified Organisms Delayed, Reuter Textline, May 13, 1992, avail-
able in LEXIS, Europe Library, Alleur File, at *2. Germany was among the first of the 
Member States, along with the Netherlands and Denmark, to ratify the two directives. 
Implementation of Biotech Rules Reassures Companies--Germany Leads the Way, Apr. 24, 1992, 
available in LEX IS, Europe Library, Alleur File, at *2. 
As of mid-1992, other Member States were still in the process of enacting the 1990 
directives. Italy has yet to implement either of the directives, and industry representatives 
there believe that this absence of legislation has delayed product development. Implemen-
tation of Biotech Rules Reassures Companies-Italy Lacks Legislation, Apr. 24, 1992, available 
in LEXIS, Europe Library, Alleur File, at *2. The UK recently published its revised 
proposals for new regulations to implement the directives; they are intended to be more 
"user-friendly" than the EC format in Decision 91/596. UK: Department of the Environment-
Proposals for New Regulations on Genetically Modified Organisms, Reuter Textline, Aug. 18, 
1992, available in LEXIS, Europe Library, Alleur File, at *1, *3. Finally, Spain has enacted 
the directives and taken the additional step of reforming its Penal Code to include prison 
sentences of two to six years for unethical genetic manipulation. Implementation of Biotech 
Rules Reassures Companies-Spain at Work on Ethics, Apr. 24, 1992, available in LEXIS, 
Europe Library, Alleur File, at *2. 
